Multispectral Optoacoustic Tomography Noninvasively Reveals Ultrastructural Muscle Changes and Associates With Clinical Disability in Inclusion Body Myositis
MedComm · 2026-12 · 7 (12)
DOI: 10.1002/mco2.71152 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 18.11.2026. Verfasst von Stefanie Meyer und 11 weiteren Autor:innen. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inclusion body myositis (IBM), the most common idiopathic inflammatory myopathy in older adults, causes progressive disability, dysphagia, and respiratory complications. Sensitive, objective and repeatable imaging biomarkers for diagnosis, staging and monitoring remain unavailable, and diagnosis continues to rely on muscle biopsy. The aim of this study was to determine whether multispectral optoacoustic tomography (MSOT) detects disease‐relevant alterations in skeletal muscle composition and provides quantitative markers of clinical impairment in IBM. Extremity muscles were examined using MSOT in 10 IBM patients and 10 age‐ and sex‐matched healthy volunteers. MSOT‐derived markers for intramuscular lipid (MSOT_LIP), collagen (MSOT_COL), deoxygenated (MSOT_Hb), and oxygenated hemoglobin (MSOT_HbO 2 ) signals were quantified and associated with muscle strength, mobility, and the IBM‐functional rating scale (IBM‐FRS). MSOT_LIP was significantly increased in IBM, particularly in leg muscles, whereas MSOT_COL was significantly reduced. Higher MSOT_LIP was associated with lower muscle strength and impaired mobility, and increased MSOT_LIP and decreased MSOT_COL were both associated with greater impairment measured by clinical assessment (IBM‐FRS and functional disability index (FDI)). MSOT noninvasively identifies disease‐relevant changes in skeletal muscle tissue composition. These quantitative readouts may complement current assessments and provide objective biomarkers for disease staging, longitudinal monitoring, and evaluation of therapeutic responses in future clinical trials. Trial Registration : The study was registered retrospectively at the German clinical trial registry (DRKS) under the registration number DRKS00033110 at 29.11.2023.
Zitieren
APA
Meyer, S., Bruex, H., Stobbe, A., Glaubitz, S., Gröhl, J., Knieling, F., Raming, R., Alves, F., Malzahn, D., Bähr, M., Haehling, S. V., & Zschüntzsch, J. (2026). Multispectral Optoacoustic Tomography Noninvasively Reveals Ultrastructural Muscle Changes and Associates With Clinical Disability in Inclusion Body Myositis. MedComm, 7(12). https://doi.org/10.1002/mco2.71152
Vancouver
Meyer S, Bruex H, Stobbe A, Glaubitz S, Gröhl J, Knieling F, et al. Multispectral Optoacoustic Tomography Noninvasively Reveals Ultrastructural Muscle Changes and Associates With Clinical Disability in Inclusion Body Myositis. MedComm. 2026;7(12). doi:10.1002/mco2.71152
BibTeX
@article{Meyer2026,
author = {Meyer, Stefanie and Bruex, Hannah and Stobbe, Alica and Glaubitz, Stefanie and Gröhl, Janek and Knieling, Ferdinand and Raming, Roman and Alves, Frauke and Malzahn, Dörthe and Bähr, Mathias and Haehling, Stephan von and Zschüntzsch, Jana},
title = {Multispectral Optoacoustic Tomography Noninvasively Reveals Ultrastructural Muscle Changes and Associates With Clinical Disability in Inclusion Body Myositis},
journal = {MedComm},
year = {2026},
volume = {7},
number = {12},
doi = {10.1002/mco2.71152}
}
EUVIMED